Search

Displaying results 1471 - 1480 of 4004 in total
  1. Drug

    Asunaprevir

    go.drugbank.com/drugs/DB11586
    ApprovedWithdrawn

    [A32528] It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113]

  2. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    Vanzacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) corrector. It is used alongside other CFTR correctors and CFTR potentiators to increase the quantity and function of CFTR at the cell surface in p...

  3. Drug

    Fondaparinux

    go.drugbank.com/drugs/DB00569
    ApprovedInvestigational

    Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. … undergoing abdominal surgery who are are at high risk of thromboembolic complications; in the treatment of deep vein thrombosis (DVT) and pumonary embolism (PE); in the management of unstable angina (UA) and non-ST

  4. Drug

    Technetium Tc-99m tilmanocept

    go.drugbank.com/drugs/DB09266
    Approved

    It may be administered via subcutaneous, intradermal, subareolar, or peritumoral injection, depending on the tutor location and planned injection technique [FDA Label]. … Technetium Tc-99m tilmanocept is a novel CD206 receptor-targeted molecule that selectively binds to mannose receptors expressed on the surface of reticuloendothelial cells in lymph nodes [A32168].

  5. Drug

    Fenoldopam

    go.drugbank.com/drugs/DB00800
    Approved

    A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.

  6. Drug

    Neon

    go.drugbank.com/drugs/DB11589
    Approved

    It is the fifth most abundant chemical element in the universe by mass but a rare element on Earth.

  7. Drug

    Trastuzumab deruxtecan

    go.drugbank.com/drugs/DB14962
    ApprovedInvestigational

    Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavabl...

  8. Drug

    Vibegron

    go.drugbank.com/drugs/DB14895
    ApprovedInvestigational

    On December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA.

  9. Drug

    Patisiran

    go.drugbank.com/drugs/DB14582
    Approved

    Patisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis . It is marketed as Onpattro which is formulated as patisiran within a liposome...

  10. Drug

    Imiglucerase

    go.drugbank.com/drugs/DB00053
    ApprovedInvestigational

    The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues.